[HTML][HTML] Therapeutic strategies for COVID-19: progress and lessons learned
G Li, R Hilgenfeld, R Whitley, E De Clercq - Nature Reviews Drug …, 2023 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
[HTML][HTML] Therapeutics for COVID-19
SS Toussi, JL Hammond, BS Gerstenberger… - Nature …, 2023 - nature.com
Vaccines and monoclonal antibody treatments to prevent severe coronavirus disease 2019
(COVID-19) illness were available within a year of the pandemic being declared but there …
(COVID-19) illness were available within a year of the pandemic being declared but there …
[HTML][HTML] Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an …
Background The safety, effectiveness, and cost-effectiveness of molnupiravir, an oral
antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the …
antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the …
[HTML][HTML] SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801
All coronaviruses known to have recently emerged as human pathogens probably
originated in bats. Here we use a single experimental platform based on immunodeficient …
originated in bats. Here we use a single experimental platform based on immunodeficient …
Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2
WP Painter, W Holman, JA Bush… - Antimicrobial agents …, 2021 - Am Soc Microbiol
ABSTRACT Molnupiravir (EIDD-2801/MK-4482), the prodrug of the active antiviral
ribonucleoside analog β-d-N4-hydroxycytidine (NHC; EIDD-1931), has activity against a …
ribonucleoside analog β-d-N4-hydroxycytidine (NHC; EIDD-1931), has activity against a …
[HTML][HTML] SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination
Dear Editor, Since the first outbreak in late 2019, the RNA genome of SARS-CoV-2 has
been undergoing constant evolution. This is largely attributed to the viral polymerase that is …
been undergoing constant evolution. This is largely attributed to the viral polymerase that is …
[HTML][HTML] Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets
Abstract The coronavirus disease 2019 (COVID-19) pandemic is having a catastrophic
impact on human health 1. Widespread community transmission has triggered stringent …
impact on human health 1. Widespread community transmission has triggered stringent …
[HTML][HTML] Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template
CJ Gordon, EP Tchesnokov, RF Schinazi… - Journal of Biological …, 2021 - ASBMB
The RNA-dependent RNA polymerase of the severe acute respiratory syndrome coronavirus
2 is an important target in current drug development efforts for the treatment of coronavirus …
2 is an important target in current drug development efforts for the treatment of coronavirus …
An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice
Coronaviruses (CoVs) traffic frequently between species resulting in novel disease
outbreaks, most recently exemplified by the newly emerged SARS-CoV-2, the causative …
outbreaks, most recently exemplified by the newly emerged SARS-CoV-2, the causative …
The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak
HA Rothan, SN Byrareddy - Journal of autoimmunity, 2020 - Elsevier
Abstract Coronavirus disease (COVID-19) is caused by SARS-COV2 and represents the
causative agent of a potentially fatal disease that is of great global public health concern …
causative agent of a potentially fatal disease that is of great global public health concern …